Oppenheimer Sticks to Its Buy Rating for Kadmon Holdings (KDMN)

By Jason Carr

Oppenheimer analyst Mark Breidenbach reiterated a Buy rating on Kadmon Holdings (KDMNResearch Report) today and set a price target of $8.00. The company’s shares closed last Tuesday at $4.20.

According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 14.8% and a 44.6% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company.

Currently, the analyst consensus on Kadmon Holdings is a Strong Buy with an average price target of $16.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.50 and a one-year low of $2.30. Currently, Kadmon Holdings has an average volume of 2.37M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.